Breast Cancer Clinical Trial
Official title:
Evaluation the Efficacy of Acupuncture in Chemotherapy Induced Peripheral Neuropathy
Peripheral neuropathy is currently the second most common side effect after chemotherapy,
second only to the side effects of blood toxicity. A variety of chemotherapy drugs may induce
peripheral neurotoxicity, and cause by the cumulative dose of chemotherapy drugs. Symptoms
include sensory parasthesia, feeling dull or numbness, glove-like feeling distributed in the
palm. The currently most effective way is to interrupt the treatment or adjust the dose of
chemotherapeutic drugs, but it is easy to make patients discontinue chemotherapy. The purpose
of this study is to explore the impact of acupuncture on neurological symptoms and quality of
life. Three kinds of questionnairs will be used:(1) Brief pain inventory- short form to
assess the extent of pain, and the impact of daily life. (2) FACT/GOG-NTX-13 (Version 4) to
assess changes in neurological symptoms; (3) WHOQOL-BREF to assess changes in the quality of
life of patients. The course of treatment was evaluated for nine weeks. Changes in
neurological function and quality of life will be evaluated before treatment, the third week
of treatment, the sixth week of treatment, till the ninth week. The aim of this study is to
confirm that acupuncture can improve peripheral neuropathy after chemotherapy, in order to
enhance breast cancer patients' quality of life, and provide the new opportunity for
integrative therapy between Chinese and Western medicine.
Keywords:acupuncture , chemotherapy-induced peripheral neuropathy
Status | Recruiting |
Enrollment | 50 |
Est. completion date | October 10, 2020 |
Est. primary completion date | October 10, 2020 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: - more than 20 yeas old Female - TypeI-IV breast cancer patients - complete chemotherapy - chemotherapeutic agents include taxanes?platinum compounds ect - ECOG<3 - NCI common terminology criteria for adverse events,v4.0: more than grade1 ? Exclusion Criteria: - average life expectancy<3months - diabetic neuropathy - inflammatory neuropathy - metabolic neuropathy - severe blood coagulopathy or bleeding tendency - unstable heart disease - neuro-muscular disease |
Country | Name | City | State |
---|---|---|---|
Taiwan | An Nan Hospital,China Medical University | Tainan |
Lead Sponsor | Collaborator |
---|---|
China Medical University Hospital |
Taiwan,
Greenlee H, Crew KD, Capodice J, Awad D, Buono D, Shi Z, Jeffres A, Wyse S, Whitman W, Trivedi MS, Kalinsky K, Hershman DL. Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | FACT/GOG-NTX-13 (Version 4) | Prorated subscale score = [Sum of item scores] x [N of items in subscale]÷ [N of items answered] For all FACIT scales and symptom indices, the higher the score the better the QOL. | 4 times in 9 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |